CLOs on the Move

Motif Neurotech

www.motifneuro.tech

 
Motif Neurotech is a clinical-stage company leading the development of minimally invasive neuromodulation therapeutics for mental health. The company`s lead product, for treatment resistant depression (TRD), is a miniature implant that is designed to treat TRD by increasing activity in the prefrontal cortex. Studies over 20 years show stimulation of the pre-frontal cortex effectively treats treatment resistant depression without the side effects of anti-depressants. However, existing brain stimulation treatments like transcranial magnetic stimulation (TMS) can be expensive and challenging for patients to access, with daily treatments required for six weeks that may need to be repeated. Human and large animal ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

ARMUS Corporation

ARMUS Corporation is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.

APS Analytical Standards

APS Analytical Standards is a Redwood City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Gallini S.R.L.

Gallini S.R.L. is a Grand Rapids, MI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Younger Optics

For more than 50 years, Younger Optics has established itself as a leader in the optical industry by developing new and innovative lens solutions. From polarized sun lenses that block blinding glare to lenses designed specifically for the driving task -

Viz

In 2015, five seminal randomized controlled trials were published in the neurovascular space demonstrating endovascular thrombectomy to be the new gold standard for treating large vessel occlusion strokes. During that same year, advancements in artificial intelligence and deep learning made it possible to analyze medical imaging rapidly and accurately. However, despite having proven effective interventions for stroke, most stroke patients were getting treatment late or not at all. At Stanford University, Dr. Chris Mansi (neurosurgeon) and Dr. David Golan (machine learning researcher) identified this problem and together they sought to change it.